SynCo Bio Partners and Versartis Expand Collaboration
SynCo Bio Partners announced an extension of its successful collaboration with Versartis, following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus patients with monthly dosing of VRS-859.
This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis’ lead product VRS-859 (exenatide-XTEN). Under the extended agreement, SynCo will scale-up a second manufacturing process on behalf of Versartis, this time in preparation for the GMP manufacture of VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency.
As with the VRS-859 program, SynCo will also provide fill and finish services for the manufacture, testing and release of formulated Drug Product vials. SynCo completed process development and optimization, scale-up and GMP manufacture of VRS-859 for Phase 1 clinical studies earlier this year.
Source:SynCo
